Bayer starts work oon $43M+ expansion of OTC manufacturing site in Pennsylvania

Date Published12/02/2022
Author NameTyler Patchen

Additional Reshoring Information:

Parent companyBayer
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2022
Year reshoring implemented or to be implemented:2025
Capital investment ($):43.6
Country(ies) from which reshored:Germany
City reshored to:Myerstown
State(s) reshored to:PA
If relevant, work nearshored to:-
Product(s) reshoredOTC Drugs
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Eco-system synergies, Higher productivity, Lean/other business process improvement techniques
Find Reshoring Articles